{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:05:57Z","timestamp":1753891557469,"version":"3.41.2"},"reference-count":6,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008130","name":"Helsinn Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Topical chlormethine yields high response rates in mycosis fungoides cutaneous T-cell lymphoma with early discontinuation often attributed to skin reactions. We evaluated over 4,000 patients and found an association of clinician case volume with treatment duration and early discontinuation of chlormethine gel. The minority of clinicians with high patient volume markedly outperformed clinicians with only few patients on both outcome parameters, yet case volume as low as five patients seemed to mark a threshold for avoiding early discontinuation of treatment regimen.<\/jats:p>","DOI":"10.3389\/fmed.2021.679294","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T06:38:38Z","timestamp":1625207918000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A Little Experience Goes a Long Way: Chlormethine\/Mechlorethamine Treatment Duration as a Function of Clinician-Level Patient Volume for Mycosis Fungoides Cutaneous T-Cell Lymphoma (MF-CTCL)\u2014A Retrospective Cohort Study"],"prefix":"10.3389","volume":"8","author":[{"given":"Christiane","family":"Querfeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Haverkos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Binder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Angello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Poligone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical Chemotherapy in Cutaneous T-cell Lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/archderm.139.2.165","article-title":"Topical nitrogen mustard in the management of mycosis fungoides: update of the stanford experience","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jdcr.2020.05.031","article-title":"Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis","volume":"6","author":"Gilmore","year":"2020","journal-title":"JAAD Case Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1396-0296.2003.01639.x","article-title":"Treatment of patch-stage mycosis fungoides with topical corticosteroids","volume":"16","author":"Zackheim","year":"2003","journal-title":"Dermatol Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"E131","DOI":"10.1188\/15.CJON.E131-E139","article-title":"Optimizing care and compliance for the treatment of mycosis fungoides cutaneous T-cell lymphoma with mechlorethamine gel","volume":"19","author":"Benjamin Chase","year":"2015","journal-title":"Clin J Oncol Nurs."},{"key":"B6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.clml.2017.05.017","article-title":"Annual facility treatment volume and patient survival for mycosis fungoides and s\u00e9zary syndrome","volume":"17","author":"Kann","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.679294\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T06:38:39Z","timestamp":1625207919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.679294\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":6,"alternative-id":["10.3389\/fmed.2021.679294"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.679294","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2021,7,2]]},"article-number":"679294"}}